Jose A S Crippa
Overview
Explore the profile of Jose A S Crippa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mendonca M, Mangiavacchi P, Mendes A, Loureiro S, Martin-Santos R, Gloria L, et al.
J Affect Disord
. 2023 Mar;
331:287-299.
PMID: 36933666
Background: The FKBP5 and NR3C1 genes play an important role in stress response, thus impacting mental health. Stress factor exposure in early life, such as maternal depression, may contribute to...
2.
Pedrazzi J, Ferreira F, Silva-Amaral D, Lima D, Hallak J, Zuardi A, et al.
Psychopharmacology (Berl)
. 2022 Jul;
239(9):2713-2734.
PMID: 35904579
Rationale: Autism spectrum disorder (ASD) is defined as a group of neurodevelopmental disorders whose symptoms include impaired communication and social interaction, restricted and repetitive patterns of behavior, and varying levels...
3.
Abichabki N, Zacharias L, Moreira N, Bellissimo-Rodrigues F, Moreira F, Benzi J, et al.
Sci Rep
. 2022 Apr;
12(1):6454.
PMID: 35440801
This study aimed to assess the ultrapure cannabidiol (CBD) antibacterial activity and to investigate the antibacterial activity of the combination CBD + polymyxin B (PB) against Gram-negative (GN) bacteria, including...
4.
Libanio T, Eufrasio R, Niigaki S, Peres F, Silva R, Zuardi A, et al.
Exp Clin Psychopharmacol
. 2021 Nov;
30(6):751-759.
PMID: 34735205
The interest in psychedelic substances as potential treatments for psychiatric disorders is increasing. The β-carboline harmine, an Ayahuasca component, presents hallucinogenic and antidepressant effects. Although Ayuahuasca-and consequently harmine-is usually consumed...
5.
Crippa J, Hallak J
Braz J Psychiatry
. 2021 Nov;
44(3):223-224.
PMID: 34730719
No abstract available.
6.
Pedrazzi J, Sales A, Guimaraes F, Joca S, Crippa J, Del Bel E
Prog Neuropsychopharmacol Biol Psychiatry
. 2021 May;
111:110352.
PMID: 34015384
Cannabidiol (CBD), a major non-psychotomimetic component of the Cannabis sativa plant, shows therapeutic potential in several psychiatric disorders, including schizophrenia. The molecular mechanisms underlying the antipsychotic-like effects of CBD are...
7.
Guimaraes T, Guimaraes M, Oliveira I, Leoni R, Santos A, Dursun S, et al.
J Clin Psychopharmacol
. 2021 Apr;
41(3):260-266.
PMID: 33857028
Background: Schizophrenia is a complex disabling mental disorder, and many patients present poor response to available treatments. Accumulating evidence about the role of the glutamate/nitric oxide pathway in mediating the...
8.
de Almeida C, Brito M, Bosaipo N, Pimentel A, Tumas V, Zuardi A, et al.
Mov Disord
. 2021 Mar;
36(7):1711-1715.
PMID: 33754375
Background: REM sleep behaviour disorder (RBD) is a common non-motor feature of Parkinson's disease (PD). Cannabidiol (CBD) is one of the main non-psychoactive components of Cannabis sativa and may represent...
9.
Machado-de-Sousa J, Crippa J, Hallak J
Curr Opin Psychiatry
. 2020 Feb;
33(3):250-254.
PMID: 32068568
Purpose Of Review: The two past decades have seen the production of a vast amount of evidence about the genetic and nongenetic factors that contribute to the onset of psychosis...
10.
Linares I, Guimaraes F, Eckeli A, Crippa A, Zuardi A, Souza J, et al.
Front Pharmacol
. 2018 Apr;
9:315.
PMID: 29674967
Cannabidiol (CBD) is a component of that has a broad spectrum of potential therapeutic effects in neuropsychiatric and other disorders. However, few studies have investigated the possible interference of CBD...